<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part7">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>7</PartID>
        <PartNumber>Part VI</PartNumber>
        <PartSequenceNumber>7</PartSequenceNumber>
        <PartTitle>Prevention</PartTitle>
        <PartChapterCount>3</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap31" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>31</ChapterID>
          <ChapterNumber>Chapter 31</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_31</ChapterDOI>
          <ChapterSequenceNumber>31</ChapterSequenceNumber>
          <ChapterTitle Language="En">Prostate Cancer Chemoprevention Strategies</ChapterTitle>
          <ChapterFirstPage>351</ChapterFirstPage>
          <ChapterLastPage>362</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>7</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_31" CorrespondingAffiliationID="Aff1_31">
              <AuthorName DisplayOrder="Western">
                <GivenName>Howard</GivenName>
                <GivenName>L.</GivenName>
                <FamilyName>Parnes</FamilyName>
              </AuthorName>
              <Contact>
                <Email>parnesh@mail.nih.gov</Email>
              </Contact>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Margaret</GivenName>
                <GivenName>G.</GivenName>
                <FamilyName>House</FamilyName>
              </AuthorName>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Joseph</GivenName>
                <GivenName>A.</GivenName>
                <FamilyName>Tangrea</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_31">
              <OrgDivision>Prostate and Urologic Cancer Research Group, NCI-Division of Cancer Prevention, Center for Cancer Research</OrgDivision>
              <OrgName>National Cancer Institute</OrgName>
              <OrgAddress>
                <City>Bethesda</City>
                <State>MD</State>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_31" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Carcinogenesis is the multistep process by which normal cells undergo malignant transformation. The clinical expression of cancer may be prevented or delayed either by risk factor modification, such as quitting smoking, or by the administration of drugs to prevent or delay the clinical expression of the malignant phenotype. This chapter focuses on the latter approach, often referred to as “chemoprevention.” Specifically, it addresses the two key issues distinguishing cancer prevention from cancer treatment agent development: selection of study endpoints and patient cohorts. In addition, a comprehensive update is provided of recently completed and ongoing phase 1, 2, and 3 prostate cancer prevention clinical trials conducted under the auspices of the Division of Cancer Prevention, NCI.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Chemoprevention</Keyword>
            <Keyword>Agent development</Keyword>
            <Keyword>Study endpoints</Keyword>
            <Keyword>Patient cohorts</Keyword>
            <Keyword>PCPT</Keyword>
            <Keyword>SELECT</Keyword>
            <Keyword>REDUCE</Keyword>
          </KeywordGroup>
          <AbbreviationGroup>
            <Heading>Abbreviations</Heading>
            <DefinitionList>
              <DefinitionListEntry>
                <Term>8-OH-dG</Term>
                <Description>
                  <Para TextBreak="No">8-Hydroxydeoxyguanosine is a marker of oxidative DNA damage</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>AR</Term>
                <Description>
                  <Para TextBreak="No">Androgen receptor</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>Bax</Term>
                <Description>
                  <Para TextBreak="No">A proapoptotic gene</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>Bcl-2</Term>
                <Description>
                  <Para TextBreak="No">An anti-apoptotic proto-oncogene</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>Caspase-3</Term>
                <Description>
                  <Para TextBreak="No">Caspases are critical effectors of apoptosis</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>cd31</Term>
                <Description>
                  <Para TextBreak="No">Membrane protein cell–cell interactions, adhesion</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>CDC6</Term>
                <Description>
                  <Para TextBreak="No">Cell division cycle 6 protein</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>CgA</Term>
                <Description>
                  <Para TextBreak="No">Chromogranin A may be useful in establishing a prostate cancer diagnosis, determining prognosis, and predicting response to treatment</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>COX</Term>
                <Description>
                  <Para TextBreak="No">Cyclooxygenase</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>DFMO</Term>
                <Description>
                  <Para TextBreak="No">α-Difluoromethylornithine</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>DHCR24</Term>
                <Description>
                  <Para TextBreak="No">Also known as seladin-1 is an anti-apoptotic protein</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>DHT</Term>
                <Description>
                  <Para TextBreak="No">Dihydrotestosterone</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>DIM</Term>
                <Description>
                  <Para TextBreak="No">3,3′-Di-indolylmethane</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>DNA</Term>
                <Description>
                  <Para TextBreak="No">Deoxyribonucleic acid</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>E</Term>
                <Description>
                  <Para TextBreak="No">Estradiol</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>ELISA</Term>
                <Description>
                  <Para TextBreak="No">Enzyme-linked immunosorbent assay</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>HGPIN</Term>
                <Description>
                  <Para TextBreak="No">High-grade prostatic intraepithelial neoplasia</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>IGF</Term>
                <Description>
                  <Para TextBreak="No">Insulin-like growth factor</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>IGFBP3</Term>
                <Description>
                  <Para TextBreak="No">Insulin-like growth factor binding protein 3</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>IHC</Term>
                <Description>
                  <Para TextBreak="No">Immunohistochemistry</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>Ki-67</Term>
                <Description>
                  <Para TextBreak="No">A marker of cellular proliferation</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>KLK2</Term>
                <Description>
                  <Para TextBreak="No">Kallikrein-related peptidase 2 serum levels of human kallikrein increase with progression from benign prostate epithelium to primary cancer and metastatic disease</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>M30</Term>
                <Description>
                  <Para TextBreak="No">A marker of apoptosis</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>MIB-1</Term>
                <Description>
                  <Para TextBreak="No">A monoclonal antibody that detects the Ki-67 antigen</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>MMP</Term>
                <Description>
                  <Para TextBreak="No">Matrix metalloproteinase</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>mRNA</Term>
                <Description>
                  <Para TextBreak="No">Messenger ribonucleic acid</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>NF-κB</Term>
                <Description>
                  <Para TextBreak="No">Nuclear factor-kappa B</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>ODD</Term>
                <Description>
                  <Para TextBreak="No">Oxidative DNA damage</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>p21</Term>
                <Description>
                  <Para TextBreak="No">A cyclin-dependent kinase cell cycle control</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>p27</Term>
                <Description>
                  <Para TextBreak="No">A cyclin-dependent kinase inhibitor cell cycle control</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>P53</Term>
                <Description>
                  <Para TextBreak="No">A tumor suppressor gene</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>Par-4</Term>
                <Description>
                  <Para TextBreak="No">Protease activated receptor 4</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>PCNA</Term>
                <Description>
                  <Para TextBreak="No">Proliferating cell nuclear antigen</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>PG</Term>
                <Description>
                  <Para TextBreak="No">Prostaglandin</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>PIN</Term>
                <Description>
                  <Para TextBreak="No">Prostatic intraepithelial neoplasia</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>PPE</Term>
                <Description>
                  <Para TextBreak="No">Polyphenon E</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>PSA</Term>
                <Description>
                  <Para TextBreak="No">Prostate-specific antigen</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>PSAV</Term>
                <Description>
                  <Para TextBreak="No">Prostate-specific antigen velocity</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>PTEN</Term>
                <Description>
                  <Para TextBreak="No">A tumor suppressor gene</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>qRT-PCR</Term>
                <Description>
                  <Para TextBreak="No">Reverse transcriptase-polymerase chain reaction</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>Se</Term>
                <Description>
                  <Para TextBreak="No">Selenium</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>Se-met</Term>
                <Description>
                  <Para TextBreak="No">Selenomethionine</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>SHBG</Term>
                <Description>
                  <Para TextBreak="No">Sex hormone binding globulin</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>T</Term>
                <Description>
                  <Para TextBreak="No">Testosterone</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>TGF-β</Term>
                <Description>
                  <Para TextBreak="No">Transforming growth factor-beta 2</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>TUNEL</Term>
                <Description>
                  <Para TextBreak="No">Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling</Para>
                </Description>
              </DefinitionListEntry>
              <DefinitionListEntry>
                <Term>VEGF</Term>
                <Description>
                  <Para TextBreak="No">Vascular endothelial growth factor</Para>
                </Description>
              </DefinitionListEntry>
            </DefinitionList>
          </AbbreviationGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Section2 ID="Sec2">
              <Heading>Carcinogenesis</Heading>
              <Para TextBreak="No">Carcinogenesis is the multistep process by which normal cells undergo malignant transformation. It is characterized by genetic and epigenetic alterations that disrupt the regulatory pathways controlling cell growth, apoptosis, and differentiation [<CitationRef CitationID="CR1_31">1</CitationRef>–<CitationRef CitationID="CR3_31">3</CitationRef>]. The observation that premalignant, noninvasive lesions often precede invasive carcinoma by decades suggests the possibility of intervening before the malignant phenotype is established [<CitationRef CitationID="CR4_31">4</CitationRef>, <CitationRef CitationID="CR5_31">5</CitationRef>]. This may be achieved by modifying behaviors, for example, smoking cessation, or through “chemoprevention,” the administration of natural or synthetic agents to reverse, inhibit, slow, or prevent the development of cancer [<CitationRef CitationID="CR6_31">6</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec3">
              <Heading>Chemoprevention</Heading>
              <Para TextBreak="No">Despite the advances in the treatment and the widespread adoption of PSA screening, prostate cancer remains the second leading cause of cancer death in the US males. Although screening clearly improves prostate cancer <Emphasis Type="Italic">survival</Emphasis>, which is subject to substantial lead-time and length bias, its impact on prostate cancer <Emphasis Type="Italic">mortality</Emphasis> is not known. This critical issue is the subject of two randomized, controlled clinical trials, and the results of which are eagerly anticipated. Even if shown to reduce prostate cancer mortality, population screening for prostate cancer will be associated with treatment-related morbidity as well as substantial financial costs. Given the inherent risks of screening, the nonmodifiable nature of the major prostate cancer risk factors (age, race, and family history), the difficulty of determining which cancers require treatment and the long natural history of this disease, prevention may be the best strategy to reduce the burden of prostate cancer.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>Prostate Cancer Prevention Clinical Trials</Heading>
            <Section2 ID="Sec5">
              <Heading>Chemoprevention Agent Development</Heading>
              <Para TextBreak="No">As the target population for cancer prevention drug therapy does not have overt disease and would likely require an extended period of treatment, chemoprevention agents must meet a very high standard with regard to toxicity, convenience, and cost. It is, therefore, not surprising that the majority of agents currently being studied for this purpose are bioactive dietary didid components. Examples include soy, lycopene, vitamins D and E, green tea catechins, and 3,3’-diindolyomethane (DIM). Supporting evidence for these and other agents has come from epidemiological observations, clinical trials, and experimental animal models [<CitationRef CitationID="CR7_31">7</CitationRef>].</Para>
            </Section2>
            <Section2 ID="Sec6">
              <Heading>Trial Endpoints</Heading>
              <Para TextBreak="No">Chemoprevention agent development poses a number of challenges not faced in cancer treatment drug development. The major issues in this regard are the identification of study cohorts and the selection of endpoints. Given the long natural history of prostate cancer, one must rely upon intermediate endpoints, for example, biomarkers of response, to obtain preliminary evidence of efficacy [<CitationRef CitationID="CR8_31">8</CitationRef>]. The major categories of biomarkers include histopathologic markers (e.g., high-grade prostatic intraepithelial neoplasia or HGPIN), tissue-based markers of proliferation and apoptosis (Ki-67 and TUNEL assays, respectively), and serum markers (e.g., PSA) [<CitationRef CitationID="CR9_31">9</CitationRef>]. The reliance on intermediate endpoints requires that studies be well controlled, preferably placebo-controlled, as comparisons of intermediate endpoints before and after an uncontrolled intervention can be difficult to interpret.</Para>
            </Section2>
            <Section2 ID="Sec7">
              <Heading>Study Cohorts</Heading>
              <Para TextBreak="No">Although appropriate cohorts for cancer treatment trials are readily defined, identifying cohorts for prostate cancer prevention studies poses a challenge. Even though the obvious answer would seem to be individuals who are at high risk of developing prostate cancer, the fact remains that all men are at substantial risk of this disease. Given the importance of tissue-based intermediate endpoint biomarkers in the evaluation of putative cancer prevention agents, the ideal candidate for a prostate cancer chemoprevention trial is a man in whom prostate tissue will be obtained during the course of standard management. Examples include men with (1) HGPIN, (2) a positive family history, (3) an elevated PSA with a negative biopsy, (4) prostate cancer being followed with “watchful waiting” (more properly referred to as “active surveillance”), and (5) men with prostate cancer scheduled for surgery, i.e., preprostatectomy cohort. The NCI is currently supporting prostate cancer chemoprevention studies in each of these cohorts (Table <InternalRef RefID="Tab1">31.1</InternalRef>).<Table Float="Yes" ID="Tab1">
                  <Caption Language="En">
                    <CaptionNumber>Table 31.1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Completed phase II chemoprevention trials: selected results NCI-sponsored prostate cancer prevention trials</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="6">
                    <colspec colname="c1" colnum="1"/>
                    <colspec colname="c2" colnum="2"/>
                    <colspec colname="c3" colnum="3"/>
                    <colspec colname="c4" colnum="4"/>
                    <colspec colname="c5" colnum="5"/>
                    <colspec colname="c6" colnum="6"/>
                    <thead>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Study design</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Cohort</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Agent</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Endpoints</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>Sample size</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Status</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Lycopene (30 or 60 mg)</SimplePara>
                          <SimplePara>6 weeks</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Tissue, serum lycopene levels</SimplePara>
                          <SimplePara>DHT, T, PSA</SimplePara>
                          <SimplePara>Ki-67, TUNEL</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>8/75</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Ongoing [<CitationRef CitationID="CR15_31">15</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Watchful waiting</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Lycopene (30 mg) vs. Omega-3 fatty acids (1 g)</SimplePara>
                          <SimplePara>3 months</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Gene expression</SimplePara>
                          <SimplePara>IGF-1, COX-2</SimplePara>
                          <SimplePara>Clinical progression</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>85/180</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Ongoing [<CitationRef CitationID="CR16_31">16</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Watchful waiting</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Isoflavones (80 mg)</SimplePara>
                          <SimplePara>3 months</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Isoflavone levels, PSA</SimplePara>
                          <SimplePara>T, E, SHBG</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>53/148</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Study completed: No effect on PSA, T, E, or SHBG [<CitationRef CitationID="CR17_31">17</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>High-risk, postradical prostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Soy protein 20 g (24 mg genistein and 40 mg total isoflavones)</SimplePara>
                          <SimplePara>24 months</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Two year PSA failure rate</SimplePara>
                          <SimplePara>Time to PSA failure</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>161/284</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Ongoing [<CitationRef CitationID="CR18_31">18</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Genistein (150, 300, 600 mg)</SimplePara>
                          <SimplePara>2–6 weeks</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Oxidative stress (ODD)</SimplePara>
                          <SimplePara>Plasma, tissue levels</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>34/80</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Study completed: Preliminary results – no change in oxidative stress biomarkers; paradoxical increase in IGF-1 in 600 mg group; increase in plasma and tissue genistein levels in treated patients [<CitationRef CitationID="CR19_31">19</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Genistein (2 mg/kg/day)</SimplePara>
                          <SimplePara>1–2 months</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Morphology (adhesion)</SimplePara>
                          <SimplePara>Gene expression</SimplePara>
                          <SimplePara>PSA, T, PCNA, apoptotic index</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>37/80</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Accrual completed: Preliminary results – altered expression of motility genes [<CitationRef CitationID="CR20_31">20</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase III, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Elevated PSA/negative biopsy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Se-yeast (200, 400 μg)</SimplePara>
                          <SimplePara>Up to 57 months</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Prostate cancer</SimplePara>
                          <SimplePara>PSAV</SimplePara>
                          <SimplePara>Prostate cancer progression: alkaline phosphatase, CgA</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>612/700</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Accrual completed: Analysis pending [<CitationRef CitationID="CR21_31">21</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Watchful waiting</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Se-yeast (200, 800 μg*)</SimplePara>
                          <SimplePara>Average duration 45 months</SimplePara>
                          <SimplePara>*800 arm dropped in 2000 due to toxicity</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>PSAV, prostate cancer progression: alkaline phosphatase, CgA</SimplePara>
                          <SimplePara>Bcl-2, Ki-67, thioredoxin reductase, glutathione peroxidase</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>159/220</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Accrual completed: Analysis pending [<CitationRef CitationID="CR21_31">21</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Healthy men</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Se-yeast</SimplePara>
                          <SimplePara>(240, 350 μg)</SimplePara>
                          <SimplePara>Se-met (200 μg)</SimplePara>
                          <SimplePara>9 months</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Plasma &amp; urine selenium concentration</SimplePara>
                          <SimplePara>DHT, T, PSA</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>0/300</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Ongoing [<CitationRef CitationID="CR22_31">22</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy or prebrachytherapy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Se-met (400 μg)</SimplePara>
                          <SimplePara>8–9 weeks</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Androgen receptor (AR) gene expression in prostate tissue
</SimplePara>
                          <SimplePara>Expression of AR related genes, e.g., PSA, KLK2, CDC6, DHCR24</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>0/70</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Ongoing [<CitationRef CitationID="CR23_31">23</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Se-met (400 μg), Finasteride (5 mg)</SimplePara>
                          <SimplePara>8–9 weeks</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>PSA gene expression</SimplePara>
                          <SimplePara>TUNEL, caspase-3, ELISA</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>0/164</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Ongoing [<CitationRef CitationID="CR24_31">24</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Se-met (200 μg)</SimplePara>
                          <SimplePara>14–31 days</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Prostate selenium concentration</SimplePara>
                          <SimplePara>Serum &amp; seminal vesicle selenium levels; PSA levels</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>68/68</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Study completed: 22% increase in prostate selenium concentration [<CitationRef CitationID="CR25_31">25</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase III, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>HGPIN</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Se-met (200 μg)</SimplePara>
                          <SimplePara>3 years</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Prostate cancer incidence</SimplePara>
                          <SimplePara>TUNEL, Ki-67</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>440/465</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Accrual completed: Analysis pending [<CitationRef CitationID="CR23_31">23</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, 2 × 2 placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Se-met (200 g), vitamin E (400 mg)</SimplePara>
                          <SimplePara>3–6 weeks</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Feasibility</SimplePara>
                          <SimplePara>Ki-67, NFkB, COX-2, p53</SimplePara>
                          <SimplePara>Tissue selenium levels</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>48/48</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Accrual competed: Analysis pending [<CitationRef CitationID="CR26_31">26</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase III, 2 × 2 × 2 × 2, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>US male physicians</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Vitamin E (400 mg), vitamin C (500 mg), multivitamin (Centrum Silver)</SimplePara>
                          <SimplePara>10 years</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Total cancer risk; vascular events</SimplePara>
                          <SimplePara>Prostate, colon cancer risk; myocardial infarction, cerebrovascular accident; macular degeneration; cognitive function</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>14,641</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Ongoing: Vitamin E and vitamin C arms closed;</SimplePara>
                          <SimplePara>multivitamin arm ongoing [<CitationRef CitationID="CR27_31">27</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase I, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Green Tea Catechins (800 mg PPE)</SimplePara>
                          <SimplePara>3–6 weeks</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Tissue catechin levles</SimplePara>
                          <SimplePara>Clusterin, MMPs, IGFs, 8-0H-dG</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>18/50</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Ongoing [<CitationRef CitationID="CR21_31">21</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo Control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>HGPIN</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Green Tea Catechins (400 mg PPE)</SimplePara>
                          <SimplePara>12 months</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Compliance, toxicity, quality of life</SimplePara>
                          <SimplePara>Prostate Cancer</SimplePara>
                          <SimplePara>NFkB, Ki-67, TUNEL</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>1/240</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Ongoing [<CitationRef CitationID="CR17_31">17</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase Ib, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>DIM (100, 200 mg)</SimplePara>
                          <SimplePara>3–4 weeks</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Tissue DIM levels</SimplePara>
                          <SimplePara>T, PSA, IGFs, AR localization Ki-67, TUNEL, caspase-3</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>45/45</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Accrual completed: Analysis pending [<CitationRef CitationID="CR28_31">28</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Hecterol (10 μg)</SimplePara>
                          <SimplePara>4–6 weeks</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Nuclear morphology</SimplePara>
                          <SimplePara>HGPIN</SimplePara>
                          <SimplePara>TUNEL, VEGF, IGFs</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>31/60</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Study completed: Preliminary results – decrease in HGPIN; decrease TGF-β; increase IGFBP3 [<CitationRef CitationID="CR29_31">29</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, historical and concurrent controls</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Sulindac sulfone (375 mg QD)</SimplePara>
                          <SimplePara>4 weeks</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Apoptosis markers: bcl-2, Bax, Par-4, M30, TUNEL, PTEN</SimplePara>
                          <SimplePara>PSA, HGPIN, MIB-1, DNA ploidy</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>105/</SimplePara>
                          <SimplePara>130</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Study completed: Prelminiary results – no differences in markers of apoptosis [<CitationRef CitationID="CR30_31">30</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Celecoxib (400 mg b.i.d.)</SimplePara>
                          <SimplePara>4–6 weeks</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Tissue PG levels</SimplePara>
                          <SimplePara>COX-2, mRNA expression, DNA oxidation, p27, p21, PCNA, and Ki-67, PSA</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>64/65</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Study completed: Preliminary results – no observed effects on PG, COX-2, and oxidized DNA base levels [<CitationRef CitationID="CR31_31">31</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase III, placebo control</SimplePara>
                          <SimplePara>“PCPT” (Prostate Cancer Prevention Trial: primary prevention)</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Age &gt; 55</SimplePara>
                          <SimplePara>PSA &lt; 3</SimplePara>
                          <SimplePara>Digital rectal exam – within normal limits</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Finasteride (5 mg/day)</SimplePara>
                          <SimplePara>7 years</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>7-Year period prevalence of prostate cancer</SimplePara>
                          <SimplePara>Gleason Score, other cancers, toxicity</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>18,882</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Study completed: Results – 24.8% decrease in 7-year period prevalence of prostate cancer [<CitationRef CitationID="CR32_31">32</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Finasteride (5 mg/day)</SimplePara>
                          <SimplePara>4–6 weeks</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Effect of finasteride on IHC markers associated with high-grade</SimplePara>
                          <SimplePara>Gleason Score</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>95/200</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Ongoing [<CitationRef CitationID="CR26_31">26</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Positive family history with negative biopsy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>DFMO (500 mg QD)</SimplePara>
                          <SimplePara>1 year</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>Prostate polyamines levels (putrescine, spermine and spermadine), PSA</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>81/100</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Study Completed: Results – significant change only in putrescine levels [<CitationRef CitationID="CR33_31">33</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="c1">
                          <SimplePara>Phase II, placebo control</SimplePara>
                        </entry>
                        <entry colname="c2">
                          <SimplePara>Preprostatectomy</SimplePara>
                        </entry>
                        <entry colname="c3">
                          <SimplePara>Toremifene (40 mg QD)</SimplePara>
                          <SimplePara>3–6 weeks</SimplePara>
                        </entry>
                        <entry colname="c4">
                          <SimplePara>HGPIN Index</SimplePara>
                          <SimplePara>bcl-2, Ki-67, cd31</SimplePara>
                          <SimplePara>DHT, T, PSA, E</SimplePara>
                        </entry>
                        <entry colname="c5">
                          <SimplePara>52/78</SimplePara>
                        </entry>
                        <entry colname="c6">
                          <SimplePara>Study completed: Preliminary results – no effect on either HGPIN or biomarkers [<CitationRef CitationID="CR34_31">34</CitationRef>]</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                </Table>
              </Para>
              <Section3 ID="Sec8">
                <Heading>HGPIN Cohort</Heading>
                <Para TextBreak="No">In the late 1990s, several small studies supported the position that the presence of HGPIN in a prostate biopsy was associated with an increased risk of cancer (as much as 40–50%) and that patients with HGPIN required close surveillance (follow-up and repeat biopsies). For example, in a study from Johns Hopkins, repeat biopsies identified cancer in 32.2% of 245 men with a prior diagnosis of HGPIN. The number of cores with high-grade PIN proved to be the only independent predictor of a cancer diagnosis: 30.2% with 1 or 2 cores, 40% with 3 cores, and 75% with &gt;3 cores [<CitationRef CitationID="CR10_31">10</CitationRef>]. The more intensive follow-up and biopsy regimen suggested for an HGPIN diagnosis made this group of patients the potential candidates for chemoprevention studies. Indeed, a few NCI-sponsored chemoprevention studies using this cohort were started during this time period and some are still underway including a phase 3, placebo-controlled trial of selenomethionine and a phase 2 study of polyphenon E. In recent years, however, larger, better-controlled studies have provided data showing that the subsequent risk of prostate cancer is not as great as originally observed and the standard of care is changing [<CitationRef CitationID="CR11_31">11</CitationRef>]. In fact, recent studies have shown that the cumulative risk of the detection of carcinoma on serial follow-up biopsies did not differ significantly between those with an initial diagnosis of HGPIN on biopsy compared with a control group, prompting reconsideration of repeat biopsy strategies for HGPIN patients [<CitationRef CitationID="CR12_31">12</CitationRef>].</Para>
              </Section3>
              <Section3 ID="Sec9">
                <Heading>Positive Family History Cohort</Heading>
                <Para TextBreak="No">Epidemiological studies indicate that dominantly inherited susceptibility genes with high penetrance may cause as much as 5–10% of all prostate cancer cases, and as much as 30–40% of early onset disease [<CitationRef CitationID="CR13_31">13</CitationRef>]. Having a brother with prostate cancer may confer a greater risk than a father [<CitationRef CitationID="CR14_31">14</CitationRef>], possibly because the gene for the androgen receptor is located on the X-chromosome. The NCI is not currently sponsoring any chemoprevention trials in men with a positive family history.</Para>
              </Section3>
              <Section3 ID="Sec10">
                <Heading>Elevated PSA, Negative Biopsy Cohort</Heading>
                <Para TextBreak="No">Men with an elevated PSA and a negative biopsy represent another potentially useful cohort for chemoprevention agent development. Although the absolute risk of finding prostate cancer on a subsequent biopsy is dependent upon the number of biopsy cores that have previously been examined, most men in this category will undergo repeat biopsies making them good candidates for clinical trials addressing intermediate biomarker endpoints. The NCI is currently sponsoring trials of high selenium yeast and soy in this cohort.</Para>
              </Section3>
              <Section3 ID="Sec11">
                <Heading>Active Surveillance Cohort</Heading>
                <Para TextBreak="No">Since men with prostate cancer being followed with active surveillance (previously referred to as “watchful waiting”) are routinely recommended to follow-up biopsies to monitor their disease status, these men represent another informative cohort for chemoprevention agent development. This group also provides an important population in whom to evaluate the usefulness of genomics and proteomics to predict the natural history of this heterogeneous disease. The NCI is currently sponsoring trials of high-selenium yeast, as well as lycopene and omega-3 fatty acids in this cohort.</Para>
              </Section3>
              <Section3 ID="Sec12">
                <Heading>Preprostatectomy Cohort</Heading>
                <Para TextBreak="No">Men with localized prostate cancer planning to undergo definitive surgery represent another highly informative cohort. Study agents are generally administered for 3–6 weeks in this model, the period of time between the diagnostic biopsy and prostatectomy. Despite the short duration of drug exposure, valuable information can be obtained regarding the effect of the study drug on intermediate endpoint biomarkers and distribution of the candidate agent in prostate tissue, since the entire gland will become available at the time of surgery. As shown in Table <InternalRef RefID="Tab1">31.1</InternalRef>, most of the drugs currently in phase 2 testing in the NCI prostate cancer chemoprevention agent development program are being evaluated in this cohort.</Para>
              </Section3>
            </Section2>
          </Section1>
          <Section1 ID="Sec13">
            <Heading>Chemoprevention Clinical Trial Program</Heading>
            <Para TextBreak="No">The Prostate and Urologic Cancers Research Group in the Division of Cancer Prevention, NCI has sponsored a number of Phase I, II, and III chemoprevention trials that are completed or currently underway. A complete list of these trials is included in Table <InternalRef RefID="Tab1">31.1</InternalRef>.</Para>
            <Para TextBreak="No">Five NCI-sponsored phase II prostate chemoprevention trials that were initiated in 2001–2003 have been completed and their data have been analyzed. All five trials employed the presurgical study design where men with localized prostate cancer are enrolled and the study agent is administered for the 3–6 weeks between diagnostic biopsy and radical prostatectomy. The primary endpoint is generally the bioavailability of the study agent in prostate tissue removed at prostatectomy. In addition, the study agent’s effect on a variety of other intermediate biomarker endpoints can be studied. These usually include general measures of cell proliferation and apoptosis as well as molecular pathway-specific targets in prostate tissue.</Para>
            <Para TextBreak="No">The five completed trials examined the prostate tissue bioavailability and biomarker modulation for celecoxib, toremifene, 1-α hydroxyvitamin D2, exisulind, and genistein. Three of the five trials employed a randomized design with a placebo control group. Of the two studies without a placebo group, one study, the 1-α-hydroxyvitamin D2 trial, used a control group randomized to observation only, while the other, the exisulind trial, attempted a unique design using concurrent and historical untreated controls as the comparison group. Only one of the five trials, the celecoxib study, reached its full accrual goal. Hence, findings from the other four are difficult to interpret because of their small sample size and consequent low statistical power to detect the differences.</Para>
            <Para TextBreak="No">The celecoxib trial was conducted at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. This was a randomized, placebo controlled trial of celecoxib in men prior to receiving prostatectomy for clinically localized prostate cancer [<CitationRef CitationID="CR31_31">31</CitationRef>]. Sixty-four men were randomized to either celecoxib 400 mg twice daily or placebo for 4–6 weeks prior to prostatectomy. The primary endpoint was the modulation of prostate tissue prostaglandin (PG) levels by celecoxib. The investigators also examined fresh frozen prostate tissue levels of COX1 and COX2 mRNA as well as the presence of oxidized DNA bases. Paraffin-based, formalin-fixed tissue slides were used to examine celecoxib effects on markers of proliferation, apoptosis, and angiogenesis. Age, baseline PSA, race, and Gleason score were comparable across intervention groups, and the treatment regimen was well tolerated with no serious adverse events. However, despite achieving measurable prostate tissue levels of celecoxib in the intervention group, no significant treatment effects on PG levels, COX mRNA levels, or oxidized DNA base levels were observed. The investigators concluded they could not recommend further studies of celecoxib at 400 mg twice daily as a prostate cancer chemopreventive agent.</Para>
            <Para TextBreak="No">The four remaining Prostate Phase II Chemoprevention trials enrolled 34–71% of their requisite sample sizes. As such, low statistical power may have contributed to the lack of significant treatment effects reported by these trials. However, some findings suggest that with a larger study sample and, perhaps, with longer exposure time, a few of these agents may have promise. For example, in a study conducted at the University of Wisconsin using a synthetic analog of vitamin D, 1-α hydroxyvitamin D2, investigators found a lower percentage of patients with HGPIN in the synthetic vitamin D group after 1 month of intervention (23 vs. 50%, <Emphasis Type="Italic">p</Emphasis> = 0.15). They also noted that patients in the vitamin D group exhibited consistent treatment group differences in the circulating plasma levels of two proteins that have been implicated in prostate cancer growth: lower levels of the growth factor, TGF-β2 (<Emphasis Type="Italic">p</Emphasis> = 0.07), and higher levels of a growth factor binding protein, IGFBP3 (<Emphasis Type="Italic">p</Emphasis> = 0.04).</Para>
            <Para TextBreak="No">Investigators at the Mayo Clinic conducted a trial to evaluate the effect of exisulind (a sulfone derivative of sulindac that has been developed as a proapoptotic agent for use in oncology) on molecular markers of apoptosis including bcl-2, Bax, Par-4, caspase-3, and PTEN. The trial employed an unusual design in that the trial was not randomized or placebo controlled. Administration of exisulind was begun 4 weeks before prostatectomy in enrolled patients. Pre-prostatectomy (i.e. base line biopsy) and post-prostatectomy levels of tissue biomarkers of apoptosis in treated patients (<Emphasis Type="Italic">n</Emphasis> = 44) were then compared with untreated prospective (<Emphasis Type="Italic">n</Emphasis> = 33) and historical (<Emphasis Type="Italic">n</Emphasis>= 24) controls selected from the same clinic population. After 4 weeks of intervention, no differences in the apoptosis markers chosen were observed. This study illustrates the importance of the randomized design, especially in clinical trials of modest size. For example, large group differences in Gleason scores for both biopsies and radical prostatectomy tissue were observed, perhaps due to differences in the time periods when cases were enrolled and controls were selected,. Only 28% of the combined prospective and historical controls had a Gleason score of 7 or greater on diagnostic biopsy compared with 48% of those in the exisulind group. This difference persisted in the prostatectomy specimens with 43% of controls having a Gleason score of 7 or greater compared with 61% of the exisulind group. These group differences in prostate cancer pathology may have contributed to the null findings regarding apoptosis.</Para>
            <Para TextBreak="No">The great advantage of the preprostatectomy study design employed in the trials described above is that the entire prostate gland can be examined following its surgical removal. This is a critical step in assessing a potential chemopreventive agent’s bioavailability in prostatic tissue and its ability to modify important drug or disease specific molecular pathways. Two major drawbacks of this design are the relatively short duration of exposure to the agent and that the intervention is given to a patient who already has prostate cancer. Nevertheless, the presurgical model will continue to be an important early step in the clinical evaluation and development of chemoprevention agents.</Para>
          </Section1>
          <Section1 ID="Sec14">
            <Heading>Phase III Prostate Cancer Chemoprevention Trials</Heading>
            <Section2 ID="Sec15">
              <Heading>The Prostate Cancer Prevention Trial</Heading>
              <Section3 ID="Sec16">
                <Heading>Overview</Heading>
                <Para TextBreak="No">Dihydrotestosterone (DHT) is the principal androgen supporting both benign and malignant prostate tissue and is an important molecular target for the chemoprevention of prostate cancer [<CitationRef CitationID="CR35_31">35</CitationRef>, <CitationRef CitationID="CR36_31">36</CitationRef>]. Testosterone (T) is reduced to DHT by the 5-alpha-reductase enzymes [<CitationRef CitationID="CR37_31">37</CitationRef>]. Rennie et al. postulated the existence of at least two isoforms of this enzyme over two decades ago, based on their observation that 5-alpha reductase isolated from the stromal and epithelial compartments differed with regard to activity level (<Emphasis Type="Italic">V</Emphasis>
                  <Subscript>max</Subscript>) and sensitivity (<Emphasis Type="Italic">K</Emphasis>
                  <Subscript>i</Subscript>) to 5-alpha reductase inhibitors [<CitationRef CitationID="CR38_31">38</CitationRef>]. It was subsequently determined that the stromal isoenzyme (type 2) is the predominant form in benign prostatic hyperplasia, whereas both the stromal and epithelial (type 1) isoforms are present in localized prostate cancer [<CitationRef CitationID="CR35_31">35</CitationRef>, <CitationRef CitationID="CR39_31">39</CitationRef>].</Para>
                <Para TextBreak="No">The Prostate Cancer Prevention Trial (PCPT) was the first large-scale, PCPT completed in the US. This phase III, placebo-controlled clinical trial evaluated finasteride, a selective inhibitor of the type 2 isoform of 5-alpha reductase, for the prevention of prostate cancer in healthy men. Between 1993 and 1996, the PCPT recruited 18,882 men aged 55 and older with a PSA of ≤3 ng/mL and a normal digital rectal examination (DRE). Study participants were randomized to receive 5 mg of finasteride or a matching placebo daily for 7 years and were followed with yearly PSA tests and DREs. Prostate biopsies were recommended for a PSA greater than 4.0 ng/mL or an abnormal DRE. Given that finasteride reduces serum PSA levels by about 50%, adjusted PSA values were reported to participants and their physicians to preserve the blind and to equalize the number of biopsies performed on the two study arms. In addition, all cancer-free men were asked to undergo an “end-of-study” prostate biopsy after 7 years on-study to reduce biases in prostate cancer detection that could have been introduced by the effects of finasteride on PSA and gland size. The primary study endpoint was the 7-year period prevalence of prostate cancer, a composite of incident cancers diagnosed “for-cause,” i.e., elevated PSAs or abnormal DRE and prevalent cancers found at “end-of-study” biopsies. The PCPT was not designed to assess the effect of finasteride on prostate cancer mortality; it was neither large enough nor of sufficiently long duration [<CitationRef CitationID="CR32_31">32</CitationRef>].</Para>
              </Section3>
              <Section3 ID="Sec17">
                <Heading>Results</Heading>
                <Para TextBreak="No">In February 2003, 15 months ahead of schedule, an independent Data and Safety Monitoring Committee (DSMC) charged with oversight of this clinical trial determined that the primary study endpoint had been reached: finasteride significantly reduced the risk of prostate cancer from 24.4 to 18.4% (<Emphasis Type="Italic">p</Emphasis> &lt; 0.001). Significant reductions were seen for incident as well as prevalent cancers, and the magnitude of risk reduction was similar for all risk groups based on age, race/ethnicity, family history, and entry PSA. In accordance with the DSMC recommendations, the trial was terminated, participants were unblinded, and the results were submitted for publication [<CitationRef CitationID="CR32_31">32</CitationRef>].</Para>
              </Section3>
              <Section3 ID="Sec18">
                <Heading>Adverse Events</Heading>
                <Para TextBreak="No">Finasteride was well tolerated despite increases in hormone-related side effects such as erectile dysfunction, reduced ejaculate volume, loss of libido, and gynecomastia. In addition, men on the finasteride arm were more likely to temporarily discontinue study drug. A quality of life analysis reported by Moinpore et al., using the Sexual Activity Scale found that the effects of finasteride on sexual function, while statistically significant, were clinically minimal (an increase of 3.21 points out of 100 or about half the intraindividual variation) and decreased with time [<CitationRef CitationID="CR40_31">40</CitationRef>]. As expected, men on finasteride had fewer urinary complaints. Significant reductions were reported in benign prostatic hyperplasia, prostatitis, urinary retention, and transurethral prostate resections (TURPs) [<CitationRef CitationID="CR32_31">32</CitationRef>].</Para>
              </Section3>
              <Section3 ID="Sec19">
                <Heading>Does Finasteride Make the Grade?</Heading>
                <Para TextBreak="No">Despite a clear benefit with regard to the primary study endpoint, finasteride was associated with a statistically significant increase in high-grade (HG) cancer. Overall, 6.4% of men on finasteride vs. 5.1% of men on placebo were diagnosed with high-grade (Gleason score 7–10) prostate cancer (<Emphasis Type="Italic">p</Emphasis> = 0.005). In total, 43 more high-grade tumors were diagnosed on the finasteride arm (280 vs. 237) [<CitationRef CitationID="CR32_31">32</CitationRef>]. Although this finding dampened enthusiasm for the use of finasteride as a preventive agent [<CitationRef CitationID="CR41_31">41</CitationRef>], the lack of a temporal relationship between exposure to finasteride and the incidence of HG cancer raised doubts as to the causal nature of this association. For example, the 2.5-fold increase in the incidence of HG cancer seen after 1 year among men on finasteride did not increase over the next 6 years on drug. In addition, the total number of HG cancers detected in men who had the longest exposure to finasteride (i.e., at end-of-study biopsy) was nearly identical in the two arms: 92 on finasteride vs. 89 on placebo [<CitationRef CitationID="CR32_31">32</CitationRef>].</Para>
                <Para TextBreak="No">Assessment of tumor grade in the PCPT was based on Gleason scores determined on biopsy specimens, as not all men diagnosed with prostate cancer underwent prostatectomy. Given the profound effect of finasteride on prostate gland size (ultrasound measurement documented a 24.1% median decrease in prostate volume in men on the finasteride arm), the investigators addressed the possibility that this drug may have introduced detection-bias both for the diagnosis of prostate cancer and of high-grade disease [<CitationRef CitationID="CR32_31">32</CitationRef>]. Indeed, a comparison of Gleason scores determined at prostatectomy in 495 men who underwent surgery (∼25% of the total number of men diagnosed with prostate cancer during the PCPT) showed the association between finasteride and HG disease to be no longer statistically significant [<CitationRef CitationID="CR42_31">42</CitationRef>]. To further explore the grade issue, more than 500 prostate biopsies on the two study arms with Gleason score ≥ 7 were examined for pathologic evidence of disease extent, a surrogate for aggressive behavior. High-grade cancers on the finasteride arm were found to be less extensive than those on the placebo arm with regard to positive cores (34 vs. 38%, <Emphasis Type="Italic">p</Emphasis> = 0.02), bilaterality (22.8 vs. 30.6%, <Emphasis Type="Italic">p</Emphasis> = 0.05), and perineural invasion (14.2 vs. 20.3%, <Emphasis Type="Italic">p</Emphasis> = 0.07), suggesting that finasteride led to earlier detection of high-grade disease [<CitationRef CitationID="CR42_31">42</CitationRef>].</Para>
                <Para TextBreak="No">The effects of finasteride on the sensitivity of PSA, DRE, and biopsy for prostate cancer detection provide a strong underlying mechanism for detection-bias. For example, at a PSA threshold providing 90.5% specificity, the sensitivity for the detection of GS &gt; 7 prostate cancer was 53% on the finasteride arm vs. only 39.2% on the placebo arm [<CitationRef CitationID="CR43_31">43</CitationRef>]. Finasteride also significantly improved the sensitivity of DRE for the overall biopsy detection of prostate cancer. Although the sensitivity of DRE for the detection of GS ≥ 7 disease was also increased by finasteride, this difference did not reach statistical significance [<CitationRef CitationID="CR44_31">44</CitationRef>]. Finally, patients found to have high-grade disease at prostatectomy were significantly more likely to have had HG disease accurately diagnosed at the time of their prostate biopsy if they were on the finasteride arm (70 vs. 51%, <Emphasis Type="Italic">p</Emphasis> = 0.01) [<CitationRef CitationID="CR42_31">42</CitationRef>].</Para>
              </Section3>
              <Section3 ID="Sec20">
                <Heading>PCPT: Conclusions</Heading>
                <Para TextBreak="No">The PCPT provided a definitive answer to the primary study question: finasteride significantly reduced the 7-year period prevalence of prostate cancer [<CitationRef CitationID="CR32_31">32</CitationRef>]. Although finasteride was associated with an increase in high-grade disease, this was a secondary finding based on Gleason scores determined at biopsy, rather than on prostatectomy specimens and was therefore subject to detection-bias. Subsequent analyses showed that finasteride significantly improved the diagnostic accuracy of PSA, DRE, and needle biopsy, leading to an underestimate of the magnitude of risk reduction and to an overestimate of the high-grade disease attributable to this agent [<CitationRef CitationID="CR42_31">42</CitationRef>, <CitationRef CitationID="CR45_31">45</CitationRef>]. Finasteride has not yet been brought to the FDA for consideration of a prevention label, however, 5-alpha reductase inhibitors may represent a particularly useful class of agents for this purpose given their beneficial effects on urinary function and amelioration of complications associated with BPH [<CitationRef CitationID="CR46_31">46</CitationRef>].</Para>
              </Section3>
            </Section2>
          </Section1>
          <Section1 ID="Sec21">
            <Heading>The Reduction by Dutasteride of Prostate Cancer Events Trial</Heading>
            <Para TextBreak="No">Reduction by Dutasteride of Prostate Cancer Events Trial (REDUCE) is a double-blind, placebo-controlled trial of dutasteride, 0.5 mg/day, for prostate cancer prevention. Dutasteride, an inhibitor of both the type 1 and 2 isoforms of 5-alpha reductase, has a more profound inhibitory effect on both serum and intraprostatic DHT levels than finasteride (described earlier) [<CitationRef CitationID="CR47_31">47</CitationRef>]. Although both isoenzymes are increased in high-grade prostate cancer, dutasteride is 45 times more effective than finasteride in inhibiting the type1 isoenzyme and twice as effective against the type 2 enzyme [<CitationRef CitationID="CR35_31">35</CitationRef>]. These observations suggest that the dual inhibitor may confer even greater protection against prostate cancer than finasteride [<CitationRef CitationID="CR39_31">39</CitationRef>].</Para>
            <Para TextBreak="No">REDUCE accrued 8,108 men aged 50–75 with PSA levels between 2.6 and 10 ng/dL (3.0–10 for men over 60 years) and a negative biopsy within 6 months of randomization. All participants were requested to have a follow-up 10-core prostate biopsy at 24 and 48 months postrandomization. The primary endpoint was the time to biopsy-proven prostate cancer. The secondary endpoints included the number and percent of cores positive for prostate cancer and the effect on Gleason score. Study results were presented by Gerald Andriole in abstract form at the April 2009 meeting of the American Urological Association. In summary, significantly fewer men randomized to dutasteride were diagnosed with prostate cancer over the course of the 4 year study (relative risk reduction 23.5%, <Emphasis Type="Italic">p</Emphasis> &lt; 0.0001). Unlike the PCPT, there was no statistically significant increase in high-grade prostate cancer, whether defined as GS 7–10 or 8–10. However, an increase in GS 8–10 cancers was noted on the dutasteride arm (19 cases or 0.6% on placebo vs. 29 cases or 0.9% on dutasteride, <Emphasis Type="Italic">p</Emphasis> = 0.15).</Para>
          </Section1>
          <Section1 ID="Sec22">
            <Heading>The Selenium and Vitamin E Cancer Prevention Trial</Heading>
            <Para TextBreak="No">Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a phase III randomized, placebo-controlled trial of selenium (200 mg/day from <Emphasis Type="SmallCaps">l</Emphasis>-selenomethionine) and/or vitamin E (400 IU/day of <Emphasis Type="Italic">all rac</Emphasis>-a-tocopheryl acetate) supplementation for prostate cancer prevention [<CitationRef CitationID="CR48_31">48</CitationRef>]. Interest in these two agents was driven primarily by secondary analyses of two earlier randomized, placebo-controlled prevention trials. The first trial (Nutritional Prevention of Cancer study) [<CitationRef CitationID="CR49_31">49</CitationRef>] suggested that selenium could reduce prostate cancer incidence by as much as two-thirds. The second (Alpha Tocopherol Beta-Carotene Study) [<CitationRef CitationID="CR50_31">50</CitationRef>] suggested that vitamin E could decrease the incidence of prostate cancer incidence and mortality by more than 30%. The hypothesis that selenium and/or vitamin E would be effective in reducing prostate cancer risk was generally supported by epidemiologic, preclinical, and other clinical data [<CitationRef CitationID="CR51_31">51</CitationRef>–<CitationRef CitationID="CR63_31">63</CitationRef>].</Para>
            <Para TextBreak="No">The major eligibility requirements for SELECT were age ≥ 55 years for non-African American men (≥ least 50 years for African American men), serum PSA ≤ 4 ng/mL, and a nonsuspicious DRE. SELECT accrued 35,533 participants between July 2001 and July 2004. At baseline, white blood cells, red blood cells, plasma, and other tissue samples (e.g., toenails) were banked for subsequent ancillary correlative studies. Annual PSA tests and DREs was not mandatory since the benefits of this screening were (and still are) under debate when the trial opened and community standards regarding prostate cancer screening were expected to evolve over the course of this planned 7–12-year trial. Participants were seen every 6 months throughout the trial for adherence and adverse events monitoring [<CitationRef CitationID="CR48_31">48</CitationRef>].</Para>
            <Para TextBreak="No">The primary endpoint of SELECT was the clinical incidence of prostate cancer. The large sample size provided 96% power to detect a 25% decrease in prostate cancer for either of the single agents vs. placebo and 89% power to detect a 25% decrease for selenium plus vitamin E vs. an active single agent. Secondary endpoints included lung, colon, and total cancer incidence, cardiovascular events, death from any cause and toxicity. In addition, four prospectively conducted substudies addressing the usefulness of selenium and vitamin E in the prevention of macular degeneration, chronic obstructive lung disease, Alzheimer’s disease, and colon polyps were performed in men already accrued to the parent study.</Para>
            <Para TextBreak="No">On 15 September 2008, following the second of five planned interim analyses, the DSMC recommended that the study supplements, vitamin E and selenium, be discontinued due to lack of efficacy. In addition, vitamin E was associated with a nonsignificant 13% increase in prostate cancer incidence (<Emphasis Type="Italic">p</Emphasis> = 0.06). A nonsignificant 7% increase in type 2 diabetes mellitus (<Emphasis Type="Italic">p</Emphasis> = 0.16) was observed in men on the selenium arm. Neither of these trends was seen in the combined vitamin E + selenium arm, which has raised some doubts regarding the validity of these observations. No significant differences were observed in any of the prespecified secondary endpoints, including toxicity [<CitationRef CitationID="CR64_31">64</CitationRef>].</Para>
            <Para TextBreak="No">These primary study findings underscore the importance of large-scale, randomized, clinical trials to definitively determine the risks and benefits of putative cancer preventive agents, including over-the-counter nutritional supplements. It should be emphasized that despite discontinuation of the study supplements, SELECT is not over. Most study participants have agreed to remain on-study and be followed in a blinded manner, which should help clarify the relationship between vitamin E and prostate cancer risk and between selenium and the risk of type 2 diabetes. It will also permit a more robust assessment of the secondary endpoints and substudies that make up a very important component of this clinical trial. Beyond that, the extensive biorepository, including prediagnostic serum and DNA from all study participants, will allow the conduct of correlative studies to better understand the biology of prostate cancer.</Para>
          </Section1>
          <Section1 ID="Sec23" Type="Conclusion">
            <Heading>Conclusions</Heading>
            <Para TextBreak="No">A great deal of progress had been made in the field of prostate cancer prevention over the past decade. Finasteride was definitively shown to reduce a man’s risk of this disease, whereas selenium and vitamin E, in the doses and formulations tested, were shown to be ineffective in this regard. The NCI phase I/II prostate cancer chemoprevention agent development program continues to expand our understanding of promising chemoprevention agents with regard to metabolism, bioavailability, and modulation of intermediate end-point biomarkers. Future agent development studies will focus on novel prevention strategies, including vaccines, combinations of agents with complementary mechanisms, surrogate endpoints, and biomarkers of risk and benefit.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_31.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_31">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Lippman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Hong</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Cancer prevention science and practice</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>62</VolumeID>
                <FirstPage>5119</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>12234971</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xnt1ynsrs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res 2002;62:5119–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_31">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KW</Initials>
                  <FamilyName>Kinzler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Vogelstein</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Lessons from hereditary colorectal cancer</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>87</VolumeID>
                <FirstPage>159</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>8861899</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0092-8674(00)81333-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XmsVGhs7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_31">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Jones</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SB</Initials>
                  <FamilyName>Baylin</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">The fundamental role of epigenetic events in cancer</ArticleTitle>
                <JournalTitle>Nat Rev Genet</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>415</FirstPage>
                <LastPage>28</LastPage>
                <Occurrence Type="PID">
                  <Handle>12042769</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrg962</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XksFOmsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415–28.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_31">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Renan</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">How many mutations are required for tumorigenesis? Implications from human cancer data</ArticleTitle>
                <JournalTitle>Mol Carcinog</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>139</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>8489711</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/mc.2940070303</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s3lslSmtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993;7:139–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_31">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WA</Initials>
                  <FamilyName>Sakr</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Prostatic intraepithelial neoplasia: A marker for high-risk groups and a potential target for chemoprevention</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>35</VolumeID>
                <FirstPage>474</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10325508</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1159/000019882</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1M3mt1Cnug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sakr WA. Prostatic intraepithelial neoplasia: A marker for high-risk groups and a potential target for chemoprevention. Eur Urol 1999;35:474–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_31">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MB</Initials>
                  <FamilyName>Sporn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Suh</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Chemoprevention: an essential approach to controlling cancer</ArticleTitle>
                <JournalTitle>Nat Rev Cancer</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>537</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>12094240</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrc844</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XkvFKltb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2002;2:537–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_31">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Parnes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>House</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kagan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Kausal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Lieberman</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Prostate cancer chemoprevention agent development: The National Cancer Institute, Division of Cancer Prevention portfolio</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>171</VolumeID>
                <FirstPage>S68</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1097/01.ju.0000107220.64675.74</Handle>
                </Occurrence>
                <BibComments>discussion S5</BibComments>
              </BibArticle>
              <BibUnstructured>Parnes HL, House MG, Kagan J, Kausal DJ, Lieberman R. Prostate cancer chemoprevention agent development: The National Cancer Institute, Division of Cancer Prevention portfolio. J Urol 2004;171:S68–74; discussion S5.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_31">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>Bostwick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Qian</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>58</VolumeID>
                <FirstPage>91</FirstPage>
                <LastPage>3</LastPage>
                <Occurrence Type="PID">
                  <Handle>11502458</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(01)01248-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3Mvlslegug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bostwick DG, Qian J. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology 2001;58:91–3.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_31">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Marzo</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VL</Initials>
                  <FamilyName>Marchi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WG</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>155</VolumeID>
                <FirstPage>1985</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>10595928</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0002-9440(10)65517-4</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_31">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Kronz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CH</Initials>
                  <FamilyName>Allan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Shaikh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy</ArticleTitle>
                <JournalTitle>Am J Surg Pathol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>1079</FirstPage>
                <LastPage>85</LastPage>
                <Occurrence Type="PID">
                  <Handle>11474294</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00000478-200108000-00014</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3MvislSgsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kronz JD, Allan CH, Shaikh AA, Epstein JI. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 2001;25:1079–85.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_31">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Herawi</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>175</VolumeID>
                <FirstPage>820</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>16469560</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-5347(05)00337-X</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006;175:820–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_31">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Godken</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Roehl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Catalona</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Humphrey</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening population</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>538</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.urology.2004.10.010</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Godken N, Roehl KA, Catalona WJ, Humphrey PA. High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening population. Urology 2005;65:538–42</BibUnstructured>
            </Citation>
            <Citation ID="CR13_31">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Langeberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WB</Initials>
                  <FamilyName>Isaacs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Stanford</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Genetic etiology of hereditary prostate cancer</ArticleTitle>
                <JournalTitle>Front Biosci</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>4101</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>17485361</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2741/2374</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXms1Kls70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Langeberg WJ, Isaacs WB, Stanford JL. Genetic etiology of hereditary prostate cancer. Front Biosci 2007;12:4101–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_31">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Noe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Schroy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MF</Initials>
                  <FamilyName>Demierre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Babayan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Geller</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Increased cancer risk for individuals with a family history of prostate cancer, colorectal cancer, and melanoma and their associated screening recommendations and practices</ArticleTitle>
                <JournalTitle>Cancer Causes Control</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>17906935</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s10552-007-9064-y</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Noe M, Schroy P, Demierre MF, Babayan R, Geller AC. Increased cancer risk for individuals with a family history of prostate cancer, colorectal cancer, and melanoma and their associated screening recommendations and practices. Cancer Causes Control 2008;19:1–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_31">
              <CitationNumber>15</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Eastham</FamilyName>
                </BibAuthorName>
                <Year>2009</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Eastham J. Personal communication; 2009.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_31">
              <CitationNumber>16</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Carroll</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <BookTitle>personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Carroll P. personal communication; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_31">
              <CitationNumber>17</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>NB</Initials>
                  <FamilyName>Kumar</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Kumar NB. Personal communication; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_31">
              <CitationNumber>18</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Bosland</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Bosland MC. Personal communication; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_31">
              <CitationNumber>19</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Kucuk</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Kucuk O. Personal communication; 2006.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_31">
              <CitationNumber>20</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Bergan</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Bergan R. Personal communication; 2006.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_31">
              <CitationNumber>21</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>FR</Initials>
                  <FamilyName>Ahmann</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Ahmann FR. Personal communication; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_31">
              <CitationNumber>22</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>El-Bayoumy</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>El-Bayoumy K. Personal communication; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_31">
              <CitationNumber>23</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Marshall</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Marshall J. Personal communication; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_31">
              <CitationNumber>24</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Ip</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Ip C. Personal communication; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_31">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Sabichi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Taylor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>2178</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="PID">
                  <Handle>16609032</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-05-0937</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XjtlChs7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sabichi AL, Lee JJ, Taylor RJ, et al. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res 2006;12:2178–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_31">
              <CitationNumber>26</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Kim J. Personal communication; 2007.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_31">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Gaziano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Glynn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WG</Initials>
                  <FamilyName>Christen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2009</Year>
                <ArticleTitle Language="En">Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>301</VolumeID>
                <FirstPage>52</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>19066368</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/jama.2008.862</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1MXntFKmsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA 2009;301:52–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_31">
              <CitationNumber>28</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Gee</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Gee J. Personal communication; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_31">
              <CitationNumber>29</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Wilding</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Wilding G. Personal communication; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_31">
              <CitationNumber>30</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>BC</Initials>
                  <FamilyName>Leibovich</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Leibovich BC. Personal communication; 2007.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_31">
              <CitationNumber>31</CitationNumber>
              <BibUnstructured>Carducci MA WJ, Heath E, et al. A randomized, placebo-controlled trial of celecoxib in men prior to receiving prostatectomy for clinically localized adenocarcinoma of the prostate: Evaluation of drug-specific biomarker modulation. J Clin Oncol (ASCO Annu Meet Proc) 2007;25:235s.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_31">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Goodman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">The influence of finasteride on the development of prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>349</VolumeID>
                <FirstPage>215</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>12824459</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa030660</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXlsVGjsbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_31">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Simoneau</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EW</Initials>
                  <FamilyName>Gerner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Nagle</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>292</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18268112</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1055-9965.EPI-07-0658</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhslarur0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Simoneau AR, Gerner EW, Nagle R, et al. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2008;17:292–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_31">
              <CitationNumber>34</CitationNumber>
              <BibBook>
                <BibAuthorName>
                  <Initials>BJ</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <BookTitle>Personal communication</BookTitle>
              </BibBook>
              <BibUnstructured>Nelson BJ. Personal communication; 2006.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_31">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Rittmaster</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>179</VolumeID>
                <FirstPage>1235</FirstPage>
                <LastPage>42</LastPage>
                <Occurrence Type="PID">
                  <Handle>18280514</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2007.11.033</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXkslKrsL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008;179:1235–42.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_31">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Parnes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LG</Initials>
                  <FamilyName>Ford</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Prevention of hormone-related cancers: prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>368</FirstPage>
                <LastPage>77</LastPage>
                <Occurrence Type="PID">
                  <Handle>15637399</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.08.027</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Parnes HL, Thompson IM, Ford LG. Prevention of hormone-related cancers: prostate cancer. J Clin Oncol 2005;23:368–77.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_31">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Bartsch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Rittmaster</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Klocker</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>37</VolumeID>
                <FirstPage>367</FirstPage>
                <LastPage>80</LastPage>
                <Occurrence Type="PID">
                  <Handle>10765065</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1159/000020181</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXis1egsLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000;37:367–80.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_31">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PS</Initials>
                  <FamilyName>Rennie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Bruchovsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>McLoughlin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FH</Initials>
                  <FamilyName>Batzold</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EE</Initials>
                  <FamilyName>Dunstan-Adams</FamilyName>
                </BibAuthorName>
                <Year>1983</Year>
                <ArticleTitle Language="En">Kinetic analysis of 5 alpha-reductase isoenzymes in benign prostatic hyperplasia (BPH)</ArticleTitle>
                <JournalTitle>J Steroid Biochem</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>169</FirstPage>
                <LastPage>73</LastPage>
                <Occurrence Type="PID">
                  <Handle>6193340</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-4731(83)80022-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL3sXltVehsb8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rennie PS, Bruchovsky N, McLoughlin MG, Batzold FH, Dunstan-Adams EE. Kinetic analysis of 5 alpha-reductase isoenzymes in benign prostatic hyperplasia (BPH). J Steroid Biochem 1983;19:169–73.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_31">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Thomas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Douglas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CB</Initials>
                  <FamilyName>Lazier</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2008</Year>
                <ArticleTitle Language="En">Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>179</VolumeID>
                <FirstPage>147</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>17997435</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2007.08.155</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thomas LN, Douglas RC, Lazier CB, et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008;179:147–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_31">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Moinpour</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AK</Initials>
                  <FamilyName>Darke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GW</Initials>
                  <FamilyName>Donaldson</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>99</VolumeID>
                <FirstPage>1025</FirstPage>
                <LastPage>35</LastPage>
                <Occurrence Type="PID">
                  <Handle>17596576</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djm023</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1025–35.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_31">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PT</Initials>
                  <FamilyName>Scardino</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">The prevention of prostate cancer – the dilemma continues</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>349</VolumeID>
                <FirstPage>297</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12824458</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMe038109</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Scardino PT. The prevention of prostate cancer – the dilemma continues. N Engl J Med 2003;349:297–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_31">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Lucia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Goodman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>99</VolumeID>
                <FirstPage>1375</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>17848673</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djm117</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1aiu7vO</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_31">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Ankerst</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Effect of finasteride on the sensitivity of PSA for detecting prostate cancer</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>98</VolumeID>
                <FirstPage>1128</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>16912265</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djj307</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xotl2ktrk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_31">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Goodman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>177</VolumeID>
                <FirstPage>1749</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>17437804</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2007.01.071</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXlsV2jtLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thompson IM, Tangen CM, Goodman PJ, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007;177:1749–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_31">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DP</Initials>
                  <FamilyName>Ankerst</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chi</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>98</VolumeID>
                <FirstPage>529</FirstPage>
                <LastPage>34</LastPage>
                <Occurrence Type="PID">
                  <Handle>16622122</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djj131</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98:529–34.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_31">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>McConnell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CG</Initials>
                  <FamilyName>Roehrborn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OM</Initials>
                  <FamilyName>Bautista</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>349</VolumeID>
                <FirstPage>2387</FirstPage>
                <LastPage>98</LastPage>
                <Occurrence Type="PID">
                  <Handle>14681504</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa030656</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXpvFGqt7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–98.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_31">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RV</Initials>
                  <FamilyName>Clark</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Hermann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Cunningham</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TH</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BB</Initials>
                  <FamilyName>Morrill</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Hobbs</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>89</VolumeID>
                <FirstPage>2179</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="PID">
                  <Handle>15126539</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.2003-030330</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjvFyrt74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89:2179–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_31">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Lippman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Goodman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Klein</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>97</VolumeID>
                <FirstPage>94</FirstPage>
                <LastPage>102</LastPage>
                <Occurrence Type="PID">
                  <Handle>15657339</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/dji009</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXmsV2jtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005;97:94–102.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_31">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LC</Initials>
                  <FamilyName>Clark</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GF</Initials>
                  <FamilyName>Combs</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BW</Initials>
                  <FamilyName>Turnbull</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1996</Year>
                <ArticleTitle Language="En">Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>276</VolumeID>
                <FirstPage>1957</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>8971064</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/jama.1996.03540240035027</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXks1eksg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Clark LC, Combs GF Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_31">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>OP</Initials>
                  <FamilyName>Heinonen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Albanes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Virtamo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>90</VolumeID>
                <FirstPage>440</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>9521168</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/90.6.440</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXitlejtbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_31">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WJ</Initials>
                  <FamilyName>Blot</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JY</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Taylor</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1993</Year>
                <ArticleTitle Language="En">Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>85</VolumeID>
                <FirstPage>1483</FirstPage>
                <LastPage>92</LastPage>
                <Occurrence Type="PID">
                  <Handle>8360931</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/85.18.1483</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3szmslygsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483–92.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_31">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Yoshizawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Willett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Morris</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>90</VolumeID>
                <FirstPage>1219</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>9719083</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/90.16.1219</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXlslylt7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_31">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Redman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Scott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AT</Initials>
                  <FamilyName>Baines</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines</ArticleTitle>
                <JournalTitle>Cancer Lett</JournalTitle>
                <VolumeID>125</VolumeID>
                <FirstPage>103</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>9566703</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0304-3835(97)00497-7</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXhtVWhtr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Redman C, Scott JA, Baines AT, et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 1998;125:103–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_31">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DG</Initials>
                  <FamilyName>Menter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Sabichi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Lippman</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Selenium effects on prostate cell growth</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>1171</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>11097224</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXos12isLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 2000;9:1171–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_31">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Stampfer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EL</Initials>
                  <FamilyName>Giovannucci</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">A prospective study of plasma selenium levels and prostate cancer risk</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>96</VolumeID>
                <FirstPage>696</FirstPage>
                <LastPage>703</LastPage>
                <Occurrence Type="PID">
                  <Handle>15126606</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djh125</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjvVSjur8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Li H, Stampfer MJ, Giovannucci EL, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004;96:696–703.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_31">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Willett</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Lessons from dietary studies in Adventists and questions for the future</ArticleTitle>
                <JournalTitle>Am J Clin Nutr</JournalTitle>
                <VolumeID>78</VolumeID>
                <FirstPage>539S</FirstPage>
                <LastPage>43S</LastPage>
                <Occurrence Type="PID">
                  <Handle>12936947</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXntFektLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Willett W. Lessons from dietary studies in Adventists and questions for the future. Am J Clin Nutr 2003;78:539S–43S.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_31">
              <CitationNumber>57</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Coates</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NS</Initials>
                  <FamilyName>Weiss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Daling</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Morris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RF</Initials>
                  <FamilyName>Labbe</FamilyName>
                </BibAuthorName>
                <Year>1988</Year>
                <ArticleTitle Language="En">Serum levels of selenium and retinol and the subsequent risk of cancer</ArticleTitle>
                <JournalTitle>Am J Epidemiol</JournalTitle>
                <VolumeID>128</VolumeID>
                <FirstPage>515</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>3046338</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1czisVersg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Coates RJ, Weiss NS, Daling JR, Morris JS, Labbe RF. Serum levels of selenium and retinol and the subsequent risk of cancer. Am J Epidemiol 1988;128:515–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_31">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Knekt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Aromaa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Maatela</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1988</Year>
                <ArticleTitle Language="En">Serum vitamin E and risk of cancer among Finnish men during a 10-year follow-up</ArticleTitle>
                <JournalTitle>Am J Epidemiol</JournalTitle>
                <VolumeID>127</VolumeID>
                <FirstPage>28</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>3276161</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1c7gtlCqtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Knekt P, Aromaa A, Maatela J, et al. Serum vitamin E and risk of cancer among Finnish men during a 10-year follow-up. Am J Epidemiol 1988;127:28–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_31">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Criqui</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Bangdiwala</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Goodman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1991</Year>
                <ArticleTitle Language="En">Selenium, retinol, retinol-binding protein, and uric acid. Associations with cancer mortality in a population-based prospective case-control study</ArticleTitle>
                <JournalTitle>Ann Epidemiol</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>385</FirstPage>
                <LastPage>93</LastPage>
                <Occurrence Type="PID">
                  <Handle>1669519</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/1047-2797(91)90008-Z</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2c%2FptlOltg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Criqui MH, Bangdiwala S, Goodman DS, et al. Selenium, retinol, retinol-binding protein, and uric acid. Associations with cancer mortality in a population-based prospective case-control study. Ann Epidemiol 1991;1:385–93.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_31">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Hsing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GW</Initials>
                  <FamilyName>Comstock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Abbey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BF</Initials>
                  <FamilyName>Polk</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>82</VolumeID>
                <FirstPage>941</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>2342127</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/82.11.941</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3c3lvVSltw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hsing AW, Comstock GW, Abbey H, Polk BF. Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. J Natl Cancer Inst 1990;82:941–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_31">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GW</Initials>
                  <FamilyName>Comstock</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Helzlsouer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TL</Initials>
                  <FamilyName>Bush</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Prediagnostic serum levels of carotenoids and vitamin E as related to subsequent cancer in Washington County, Maryland</ArticleTitle>
                <JournalTitle>Am J Clin Nutr</JournalTitle>
                <VolumeID>53</VolumeID>
                <FirstPage>260S</FirstPage>
                <LastPage>4S</LastPage>
                <Occurrence Type="PID">
                  <Handle>1985396</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3M%2FptVShtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Comstock GW, Helzlsouer KJ, Bush TL. Prediagnostic serum levels of carotenoids and vitamin E as related to subsequent cancer in Washington County, Maryland. Am J Clin Nutr 1991;53:260S–4S.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_31">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Eichholzer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HB</Initials>
                  <FamilyName>Stahelin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KF</Initials>
                  <FamilyName>Gey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Ludin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Bernasconi</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study</ArticleTitle>
                <JournalTitle>Int J Cancer</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>145</FirstPage>
                <LastPage>50</LastPage>
                <Occurrence Type="PID">
                  <Handle>8603802</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0215(19960410)66:2&lt;145::AID-IJC1&gt;3.0.CO;2-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK287nvFCrsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Eichholzer M, Stahelin HB, Gey KF, Ludin E, Bernasconi F. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 1996;66:145–50.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_31">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Chan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Stampfer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Ma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EB</Initials>
                  <FamilyName>Rimm</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Willett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EL</Initials>
                  <FamilyName>Giovannucci</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>893</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>10548318</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXns1CrtLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999;8:893–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_31">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Lippman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Klein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Goodman</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2009</Year>
                <ArticleTitle Language="En">Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)</ArticleTitle>
                <JournalTitle>JAMA</JournalTitle>
                <VolumeID>301</VolumeID>
                <FirstPage>39</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>19066370</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1001/jama.2008.864</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1MXntFKmsw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39–51.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
